secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-040057
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Q3 rev $1.2M, net loss $7.1M; OpRegen Phase 2a enrolling
---------------------------------------------------------------------

- Revenue $1.2M, down 60% YoY from $3.0M; net loss $7.1M ($0.04/sh) vs $6.1M ($0.04/sh) prior year.
- Cash $41.3M, expected to fund operations into Q1 2025.
- OpRegen Phase 2a in GA secondary to AMD enrolling under Genentech; new data showed rapid retinal structural improvements within 3 months in 5 patients.
- On track to submit OPC1 IND amendment in Q4 2023 for spinal cord injury DOSED study.
- Initiated hypoimmune pluripotent cell line development with Eterna Therapeutics; selected B2M deletion, HLA-E insertion, and third undisclosed edit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/0001493152-23-040057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer